0001817048-22-000002.txt : 20220519 0001817048-22-000002.hdr.sgml : 20220519 20220519091525 ACCESSION NUMBER: 0001817048-22-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20220519 DATE AS OF CHANGE: 20220519 EFFECTIVENESS DATE: 20220519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gilgamesh Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001817048 IRS NUMBER: 842552195 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-446192 FILM NUMBER: 22941267 BUSINESS ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 BUSINESS PHONE: 347-967-6831 MAIL ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 D 1 primary_doc.xml X0708 D LIVE 0001817048 Gilgamesh Pharmaceuticals, Inc. 113 University Place Suite 1019 New York NY NEW YORK 10003 3479676831 DELAWARE None None Corporation true 2019 Jonathan Sporn 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Andrew Kruegel 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Robert Berman 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Phil Skolnick 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Amy Kruse 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Yoni Falkson 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Laszlo Kiss 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Gerard Marek 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Thomas Kevin Murphy 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Gaetano Crupi 113 University Place Suite 1019 New York NY NEW YORK 10003 Director Pharmaceuticals Decline to Disclose 06c false 2022-05-16 false true true Shares of preferred stock of Issuer (Preferred Shares), and the shares of capital stock of the Issuer into which the Preferred Shares may convert. false 50000 50000001 13761009 36238992 false 14 0 0 0 true Some of the proceeds will be used to pay the salaries of the officers of the Issuer in the ordinary course of business. false Gilgamesh Pharmaceuticals, Inc. John Fallone /s/ John Fallone Attorney for Issuer 2022-05-19